Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases.
鈉-葡萄糖共轉運蛋白 2 抑制劑在心臟病和腎臟病中的孟德爾隨機化研究。
J Int Med Res 2024-08-31
[Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
心血管疾病患者中帶有和不帶有慢性腎臟疾病的鈉葡萄糖共同轉運蛋白2抑製劑的腎臟效應。
G Ital Cardiol (Rome) 2023-03-08
Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
腎功能不同對鈉葡萄糖共轉運蛋白2抑制劑在心血管和腎臟結果上的差異影響:涉及10個隨機臨床試驗和71,553名個體的劑量反應荟萃分析。
Eur J Endocrinol 2023-08-04
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: A mendelian randomization and population-based cohort study.
抑制鈉葡萄糖共同轉運蛋白-2對糖尿病患者肝臟相關併發症的影響:Mendelian randomization和人群基礎的 cohort 研究。
Hepatology 2024-03-11
SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study.
SGLT2 抑制、靜脈血栓形成和心臟原因死亡:一項中介 Mendelian 隨機化研究。
Front Cardiovasc Med 2024-05-28
Deciphering the Causal Relationship between Sodium-glucose Cotransporter 2 Inhibition and Cancer Risks: A Comprehensive Mendelian Randomization Study.
藉由全面的Mendelian Randomization研究解讀鈉葡萄糖共轉運輸蛋白2抑制與癌症風險之因果關係。
J Cancer 2024-06-24
Assessment of the effect of the SLC5A2 gene on eGFR: a Mendelian randomization study of drug targets for the nephroprotective effect of sodium-glucose cotransporter protein 2 inhibition.
SLC5A2 基因對 eGFR 影響的評估:一項針對鈉-葡萄糖共轉運蛋白 2 抑制的腎保護效果藥物靶點的孟德爾隨機化研究。
Front Endocrinol (Lausanne) 2024-09-13